Or yi S. Street 2, 1083, Budapest, Hungary. 21st Department of Pathology and
Or yi S. Street 2, 1083, Budapest, Hungary. 21st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary. 3 Department of Internal Medicine, St Rokus Hospital, Budapest, Hungary. Received: 24 March 2012 Accepted: 27 April 2012 Published: 11 July 2012 References 1. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003, 348(11):994?004. 2. Bumbea H, Vladareanu AM, Voican I, Cisleanu D, Barsan L, Onisai M: Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors he first molecular targeted treatment. J Med Life. 2010, 3(2):162?. 3. Aguilera DG, Tsimberidou AM: Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag. 2009, 5(2):281?. B, Smith BD: Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib. Clin Ther. 2010, 32(5):804?0. Traer E, Deininger MW: How much and how long: tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2010, 10(Suppl 1):S20?. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010, 11(11):1029?5. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R: Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009, 27(35):6041?1.doi:10.1186/2162-3619-1-17 Cite this article as: Gad?et al.: Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia. Experimental Hematology Oncology 2012 1:17.AG-490 chemical information submit your next manuscript to BioMed Central and take full advantage of:?Convenient online submission ?Thorough peer review ?No space constraints or color figure charges ?Immediate publication on acceptance ?Inclusion in PubMed, CAS, Scopus and PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/26437915 Google Scholar ?Research which is freely available for redistributionSubmit your manuscript at www.biomedcentral.com/submit
Tirado et al. Experimental Hematology Oncology 2012, 1:21 http://www.ehoonline.org/content/1/1/Experimental Hematology OncologyCASE REPORTOpen Access”T-cell prolymphocytic leukemia (T-PLL), a heterogeneous disease exemplified by two cases and the important role of cytogenetics: a multidisciplinary approach”Carlos A Tirado1*, Phillip Starshak1, Paul Delgado2 and Nagesh RaoAbstractT-cell prolymphocytic leukemia (T-PLL) is a rare form of leukemia composed of mature T-cells that usually presents in older people with a median age of 65. Most cases of T-PLL will harbor chromosomal abnormalities involving 14q11.2 (TCR alpha/delta), 14q32 (TCL1) or Xq28 (MTCP-1), abnormalities of chromosome 8, 12p and deletions of the long arm of chromosome.